- Company
- Will Astellas’ gastric cancer drug Vyloy be approved in 2H?
- by Eo, Yun-Ho Aug 19, 2024 05:47am
- Zolbetuximab, a new targeted cancer therapy with a new mechanism of action for gastric cancer, may be commercialized in Korea in the second half of the year. According to industry sources, the Ministry of Food and Drug Safety (MFDS) is currently reviewing Vyloy (zolbetuximab), a treatment for patients with CLDN18.2 positive, unresectable,
- Company
- Entresto faces competition in the heart failure market
- by Moon, sung-ho Aug 19, 2024 05:47am
- As the volume of treatment for patients with heart failure increases due to the aging population, the competition is accelerating in the market for the treatment. This is because there are more treatment options in clinical practices and higher chances of generics entry into the market. According to the medical and pharmaceutical indu
- Policy
- Will Paxlovid soon be reimbursed in Korea?
- by Lee, Tak-Sun Aug 19, 2024 05:47am
- The government has announced that it will expedite the insurance listing process for COVID-19 drugs due to COVID-19 resurgence in Korea. As a result, attention is focused on whether the government will speed up the reimbursement coverage of the COVID-19 drug Paxlovid, which has remained under review by Korea’s Health Insurance Review a
- Policy
- KDCA operates Public-Private Council for COVID-19 response
- by Kang, Hye-Kyung Aug 16, 2024 05:56am
- The Korea Disease Control and Prevention Agency (KDCA) announced that it will do its utmost to respond to COVID-19 by reorganizing its COVID-19 task force and forming a public-private council with experts. The agency expects the outbreak to continue until the end of August. On the 13th, the KCDA said, “The number of hospitalized COVID
- Company
- Twice-yearly Uplizna enters last stage to reimb in KOR
- by Eo, Yun-Ho Aug 16, 2024 05:56am
- Uplizna, a new drug for neuromyelitis optica spectrum disorder (NMOSD) that is administered twice a year, has entered the final gateway for insurance reimbursement in Korea. According to industry sources, Mitsubishi Tanabe Pharma Korea entered pricing negotiations with the National Health Insurance Service (NHIS) for Uplizna (inebilizumab
- Company
- OraTicx signs a distribution deal with U.S.-based Stratum
- by Son, Hyung-Min Aug 16, 2024 05:56am
- OraTicx, a company specializing in developing oral probiotics, announced that it has signed an exclusive distribution agreement for the North American region with Stratum Nutrion (hereafter referred to as Stratum), a U.S.-based dietary supplement ingredient supplier. Through this agreement, OraTicx will exclusively distribute its propriet
- Policy
- KDCA 'COVID-19 drug supply will be stabilized within August'
- by Lee, Hye-Kyung Aug 16, 2024 05:55am
- The government has explained that pharmacies nationwide will have enough COVID-19 drugs by the last week of August. In the case of self-test kits, the government added that it plans to produce and supply more than 5 million kits within August to ensure no shortage. The Ministry of Health and Welfare (Minister Kyoo-hong Cho) held a joint meeti
- Company
- K-Pharma speeds up marketing new drugs for bile duct cancer
- by Son, Hyung-Min Aug 16, 2024 05:55am
- Korean pharmaceutical companies are speeding up the development of new drugs for cholangiocarcinoma (also known as bile duct cancer). Handok's partnering company in the United States, Compass Therapeutics, has recently completed registering patients for the Phase 2/3 trials. Once the efficacy of the novel drug is confirmed, Handok plans to apply
- Will Keytruda be reimb for its 17 indications in 2H?
- by Eo, Yun-Ho Aug 14, 2024 05:51am
- Whether any progress will be made in the immuno-oncology drug Keytruda’s reimbursement journey in the second half of the year is gaining attention. The application, which was first filed for 13 indications, has now grown to request coverage for 17 indications. In June last year, MSD Korea applied to extend the reimbursement coverage of i
- Company
- LG Chem begins Phase 2 trials for infant hexavalent vaccine
- by Hwang, Byung-woo Aug 14, 2024 05:51am
- LG Chem prepares to commence the Phase 2 clinical trial for its hexavalent vaccine LR20062. The company aims to domestically produce infant combination vaccines in South Korea. Since South Korea has so far relied entirely on imported combination vaccines, the company plans to provide a stable supply network to meet mid- to-long term dema
